{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:07:09Z","timestamp":1783948029860,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"DOI":"10.1038\/s44321-024-00036-y","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:02:06Z","timestamp":1709013726000},"page":"672-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Promoting expression in gene therapy: more is not always better"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-7155","authenticated-orcid":false,"given":"Maria M","family":"Zwartkruis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-9444","authenticated-orcid":false,"given":"Ewout JN","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"36_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, Sun R, Tauscher-Wisniewski S, Kaufmann P, Kullak-Ublick G (2021) Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol 74:560\u2013566","journal-title":"J Hepatol"},{"key":"36_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","volume":"27","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Perenthaler E, Courtney NL, Jordan CY, Shorrock HK, van der Hoorn D, Huang YT, Murray LM, Viero G, Gillingwater TH (2018) Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Hum Mol Genet 27:2851\u20132862","journal-title":"Hum Mol Genet"},{"key":"36_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, Richman LK, Wilson JM (2018) Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 29:285\u2013298","journal-title":"Hum Gene Ther"},{"key":"36_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","volume":"22","author":"Q Ling","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ (2023) AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov 22:789\u2013806","journal-title":"Nat Rev Drug Discov"},{"key":"36_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52","journal-title":"Nat Rev Dis Primers"},{"key":"36_CR7","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","volume":"129","author":"DM Ramos","year":"2019","unstructured":"Ramos DM, d\u2019Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, Matson J, Taylor SJ, Zaworski PG, Prior TW et al (2019) Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Investig 129:4817\u20134831","journal-title":"J Clin Investig"},{"key":"36_CR8","doi-asserted-by":"publisher","first-page":"dmm050352","DOI":"10.1242\/dmm.050352","volume":"16","author":"I Signoria","year":"2023","unstructured":"Signoria I, Van Der Pol WL, Groen EJN (2023) Innovating spinal muscular atrophy models in the therapeutic era. Dis Models Mech 16:dmm050352","journal-title":"Dis Models Mech"},{"key":"36_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen G, Burghes AHM, Hsieh C, Do J, Chu BTT, Perry S, Barkho B, Kaufmann P, Sproule DM, Feltner DE et al (2021) Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med 27:1701\u20131711","journal-title":"Nat Med"},{"key":"36_CR1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestr\u00e9e N, Recinos Y, Workman E, Shihabuddin LS, Zhang C, Mentis GZ, Pellizzoni L (2021) Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci 24:930\u2013940","journal-title":"Nat Neurosci"},{"key":"36_CR10","doi-asserted-by":"crossref","unstructured":"Xie Q, Chen X, Ma H, Zhu Y, Ma Y, Jalinous L, Cox GF, Weaver F, Yang J, Kennedy Z et al (2024) Intravenous AAV9 gene therapy for spinal muscular atrophy: improved safety and efficacy using a codon-optimized SMN1 transgene and an endogenous SMN1 promotor in a SMA mouse model. EMBO Mol Med (this issue)","DOI":"10.1038\/s44321-024-00037-x"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00036-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:43:31Z","timestamp":1779065011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,15]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00036-y","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}